Chimeric antigen receptor modified T cells directed against CD19 (CTL019) in patients with relapsed, refractory CLL: a systematic review and meta-analysis
American Journal of Blood Research · 2025
DOI: 10.62347/wdwe6603 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift American Journal of Blood Research, 2025. Verfasst von Mohammad Amin Karimi und 19 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Shahid Beheshti University of Medical Sciences Tehran, Iran. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Medicine, Shahid Beheshti University of Medical Sciences Tehran, Iran.
- Student Research Committee, School of Nursing and Midwifery, Shahid Sadoughi University of Medical Sciences Yazd, Iran.
- Student Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences Mashhad, Iran.
- Student Research Committee, School of Medicine, Isfahan University of Medical Sciences Isfahan, Iran.
- Student Research Committee, School of Medicine, Islamic Azad University Tehran Medical Branch Tehran, Iran.
- Universal Scientific Education and Research Network (USERN) Tehran, Iran.
Zitieren
APA
Karimi, M. A., Rouhparvarzamin, M., Kahdemi, R., Dadkhah, P. A., Karimi, N., Nasiri, P., Azizinezhad, A., Mashhadian, A., Alizadeh, H., Arghidash, F., Valizadegan, P., Ehsani Ziary, S., Akhtari Kohnehshahri, A., Feyzi, K., Salimi, O., Hashemi, S. H., Gholami Chahkand, M. S., Khakpour, Y., Arab Bafrani, M., & Deravi, N. (2025). Chimeric antigen receptor modified T cells directed against CD19 (CTL019) in patients with relapsed, refractory CLL: a systematic review and meta-analysis. American Journal of Blood Research. https://doi.org/10.62347/wdwe6603
Vancouver
Karimi MA, Rouhparvarzamin M, Kahdemi R, Dadkhah PA, Karimi N, Nasiri P, et al. Chimeric antigen receptor modified T cells directed against CD19 (CTL019) in patients with relapsed, refractory CLL: a systematic review and meta-analysis. American Journal of Blood Research. 2025. doi:10.62347/wdwe6603
BibTeX
@article{Karimi2025,
author = {Karimi, Mohammad Amin and Rouhparvarzamin, Motahareh and Kahdemi, Reza and Dadkhah, Parisa Alsadat and Karimi, Narges and Nasiri, Parisa and Azizinezhad, Arash and Mashhadian, Aseman and Alizadeh, Haleh and Arghidash, Faezeh and Valizadegan, Pooyan and Ehsani Ziary, Shayan and Akhtari Kohnehshahri, Ata and Feyzi, Kamyar and Salimi, Omid and Hashemi, Seyed Hadi and Gholami Chahkand, Mohammad Sadra and Khakpour, Yaser and Arab Bafrani, Melika and Deravi, Niloofar},
title = {Chimeric antigen receptor modified T cells directed against CD19 (CTL019) in patients with relapsed, refractory CLL: a systematic review and meta-analysis},
journal = {American Journal of Blood Research},
year = {2025},
doi = {10.62347/wdwe6603}
}
EUVIMED